-
EP3699198
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3699198
| EP3699198 - METHODS FOR TUMOR TREATMENT USING CD3XCD20 BISPECIFIC ANTIBODY [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 21.02.2025 Database last updated on 26.04.2025 | |
| Former | Grant of patent is intended Status updated on 10.11.2024 | ||
| Former | Examination is in progress Status updated on 24.02.2023 | ||
| Former | Request for examination was made Status updated on 26.02.2021 | ||
| Former | The application has been published Status updated on 24.07.2020 | Most recent event Tooltip | 21.02.2025 | (Expected) grant | published on 26.03.2025 [2025/13] | Applicant(s) | For all designated states Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | [2020/35] | Inventor(s) | 01 /
SMITH, Eric c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill, River Road Tarrytown, NY 10591 / US | 02 /
DAVIS, Samuel c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill, River Road Tarrytown, NY 10591 / US | 03 /
VARGHESE, Bindu c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill, River Road Tarrytown, NY 10591 / US | 04 /
KIRSHNER, Jessica R. c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill, River Road Tarrytown, NY 10591 / US | 05 /
THURSTON, Gavin c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill, River Road Tarrytown, NY 10591 / US | 06 /
LOWY, Israel c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill, River Road Tarrytown, NY 10591 / US | 07 /
BROWNSTEIN, Carrie c/o Regeneron Pharmaceuticals Inc. 777 Old Saw Mill, River Road Tarrytown, NY 10591 / US | [2020/35] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2025/13] |
| Former [2020/35] | J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 20167215.1 | 17.11.2015 | [2020/35] | Priority number, date | US201462080716P | 17.11.2014 Original published format: US 201462080716 P | US201562160788P | 13.05.2015 Original published format: US 201562160788 P | [2020/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3699198 | Date: | 26.08.2020 | Language: | EN | [2020/35] | Type: | B1 Patent specification | No.: | EP3699198 | Date: | 26.03.2025 | Language: | EN | [2025/13] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 09.07.2020 | Classification | IPC: | C07K16/28, G01N33/50, A61K39/00, A61P35/02 | [2020/35] | CPC: |
C07K16/2809 (EP,IL,KR,US);
A61K39/395 (IL,KR);
A61K39/39566 (IL,US);
A61P35/02 (EP,IL,US);
C07K16/2887 (EP,IL,KR,US);
A61K2039/505 (EP,IL,KR,US);
A61K2039/545 (EP,IL,KR,US);
C07K2317/31 (EP,IL,KR,US);
C07K2317/53 (IL,KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/13] |
| Former [2020/35] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | VERFAHREN ZUR TUMORBEHANDLUNG MIT BISPEZIFISCHEM CONCURRENT IMAGE-ANTIKÖRPER | [2020/35] | English: | METHODS FOR TUMOR TREATMENT USING CD3XCD20 BISPECIFIC ANTIBODY | [2020/35] | French: | PROCÉDÉS POUR LE TRAITEMENT DE TUMEURS À L'AIDE D'ANTICORPS BISPÉCIFIQUES CD3XCD20 | [2020/35] | Examination procedure | 24.02.2021 | Examination requested [2021/13] | 24.02.2021 | Date on which the examining division has become responsible | 23.03.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 28.05.2021 | Amendment by applicant (claims and/or description) | 27.02.2023 | Despatch of a communication from the examining division (Time limit: M04) | 30.06.2023 | Reply to a communication from the examining division | 11.11.2024 | Communication of intention to grant the patent | 17.02.2025 | Fee for grant paid | 17.02.2025 | Fee for publishing/printing paid | 17.02.2025 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP15801637.8 / EP3221359 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 28.05.2021 | Request for further processing filed | 28.05.2021 | Full payment received (date of receipt of payment) Request granted | 09.06.2021 | Decision despatched | Fees paid | Renewal fee | 31.03.2020 | Renewal fee patent year 03 | 31.03.2020 | Renewal fee patent year 04 | 31.03.2020 | Renewal fee patent year 05 | 19.11.2020 | Renewal fee patent year 06 | 18.11.2021 | Renewal fee patent year 07 | 22.11.2022 | Renewal fee patent year 08 | 22.11.2023 | Renewal fee patent year 09 | 21.11.2024 | Renewal fee patent year 10 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2014047231 (REGENERON PHARMA [US]); | [Y]WO2014121087 (REGENERON PHARMA [US]); | [YP]WO2015143079 (REGENERON PHARMA [US]); | by applicant | US4361549 | US5500362 | US5736137 | US5821337 | WO2005103081 | US7087411 | US2007280945 | US2009142354 | US7879984 | US2011027286 | US2011195454 | WO2013166236 | WO2014121087 | WO2013US60511 |